MedTrace Logo

Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

NCT03461575 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2020-05-08

No results posted yet for this study

Summary

A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

Conditions

  • Dry Eye Syndrome

Interventions

DRUG

HU007

cyclosporine 0.02%, trehalose 3%

DRUG

Restasis

cyclosporine 0.05%

DRUG

Moisview

trehalose 3%

Sponsors & Collaborators

  • Huons Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Namsick Kim · Huons Co., Ltd.

  • Choun-Ki Joo · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2018-07-12
Completion
2018-07-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03461575 on ClinicalTrials.gov